NCT07537881 2026-04-17
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Not yet recruiting
RemeGen Co., Ltd.
RemeGen Co., Ltd.
Tcelltech Inc.
BPGbio
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RemeGen Co., Ltd.